AKTX

Akari Therapeutics Plc operates as a clinical-stage biopharmaceutical company focused on developing advanced therapies for autoimmune and inflammatory diseases. Headquartered in London, United Kingdom, with operations in the United States, the company specializes in treatments targeting the complement and leukotriene pathways. Akari's lead product candidate, nomacopan, is a recombinant small protein inhibitor of complement C5 and leukotriene B4, currently in development for rare diseases including bullous pemphigoid, a serious autoimmune blistering skin disease, and pediatric hematopoietic stem cell transplant-associated thrombotic microangiopathy. The company utilizes a bispecific mechanism of action designed to provide dual therapeutic benefits by simultaneously blocking inflammation pathways. In recent years, Akari has restructured its clinical development strategy, focusing resources on its most promising indications and advancing nomacopan through Phase II and Phase III trials. The company operates with a lean organizational structure typical of clinical-stage biotechnology firms, prioritizing research and development expenditures. Akari's ordinary shares trade on the Nasdaq Capital Market under the ticker symbol AKTX. The company faces significant competition in the complement inhibition space from both established pharmaceutical companies and emerging biotechnology firms, though it seeks to differentiate through nomacopan's dual mechanism and potential for treating multiple rare disease indications.